Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Genitourinary 1

Conditions

Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Melanoma 4Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Sarcoma 2Ovarian Neoplasms 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Neoplasms, Squamous Cell 1Neoplasms, Plasma Cell 1Metastatic Castration-resistant Prostate Cancer 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Kidney Neoplasms 1Chondrosarcoma 1Carcinoma, Transitional Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Nivolumab 5pembrolizumab 4Ipilimumab 2Drug Therapy 2Biopsy 2poly ICLC 1pertuzumab 1osimertinib 1montanide ISA 51 1liposomal doxorubicin 1flt3 ligand protein 1cobimetinib 1cemiplimab 1cc-486 1brodalumab 1Trastuzumab 1Tissue Banks 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × poly ICLC × Genitourinary × Clear all
NCT02897765 2021-02-25

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

BioNTech SE

Phase 1 Completed
34 enrolled
DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡